Clinical trial
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
NCT01316237 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2011
- Completion date
- January 31, 2012
- Enrollment
- 90 (estimated)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.